

CURZIO RÜEGG, M.D.**1. Personal data**

Name, First names Rüegg, Curzio Roberto Maria
 Date of birth February 11, 1958, Bellinzona (Switzerland)
 Citizenship Swiss
 Professional address Pathology Unit, Department of Oncology, Microbiology and Immunology
 Faculty of Sciences and Medicine, University of Fribourg
 Chemin du Musée 18, Per 17, 1.33, 1700 Fribourg, Switzerland
 Tel: +41-26-300-8766; Fax: +41-26-300- 9733
 E-mail: curzio.ruegg@unifr.ch : URL: <https://www3.unifr.ch/med/de/research/groups/ruegg>
 Languages Mother tongue: Italian; Fluent: German, French, English
 ORCID ID 0000-0001-9137-7695

2. Current position

2010-present Full Professor, Chair of Pathology
 President, Department of Oncology, Microbiology and Immunology
 Faculty of Science and Medicine, University of Fribourg Switzerland

3. Area of research

Experimental and translational cancer research in tumor immunity and metastasis; Mechanisms of resistance to anticancer treatments; Cancer biomarkers.

4. Education

1986 Doctoral degree in Medicine, University of Basel, Switzerland
 1985 Federal diploma of Physician, University of Basel, Switzerland

5. Postgraduate training

1989 – 1993 Postdoctoral Fellow, Lung Biology Center, School of Medicine, UCSF, USA
 1988 – 1989 Intern, Dept. of Internal Medicine *Ospedale San Giovanni*, Bellinzona, Switzerland
 1986 – 1988 Postdoctoral Fellow, Dept. of Allergy and Inflammation, CIBA-GEIGY AG, Basel,
 1986 PG course in experimental medicine and biology, University of Zurich

6. Professional appointments

2022 – present Individual Member of the Senate of the Swiss Academy of Medical Sciences
 2010 – present Chair of Pathology, Department of Oncology, Microbiology and Immunology
 Faculty of Sciences and Medicine, University of Fribourg, Switzerland
 2006 – 2010 Head, Division of Experimental Oncology, *Médecin Chef*, CePO-CHUV-University of Lausanne,
 Switzerland
 2002 – 2006 Affiliate Member, ISREC, Epalinges, Switzerland
 1993 – 2005 Head of Research, CePO, Faculty of Biology and Medicine, University of Lausanne

7. Academic appointments

2010 – present Full Professor of Pathology, University of Fribourg
 2003 – present Associate Professor of Experimental Oncology, University of Lausanne
 1999 – 2003 Assistant Professor of Experimental Oncology, University of Lausanne

8. Administrative responsibilities

2018 – 2022 President, Department of Oncology, Microbiology and Immunology, University of Fribourg
 2013 – 2020 Deputy Director, NCCR bioinspired materials (Leading House: UNIFR)
 2011 – 2013 President, DepMed, University of Fribourg
 2010 – 2011 Vice President, DepMed, University of Fribourg
 2010 – 2013 Member of the Faculty Committee, Faculty of Science, UNIFR, Fribourg
 2010 – 2018 Head of the Research Committee, DepMed, University of Fribourg
 2008 – 2010 Member of *bureau de direction* Multidisciplinary Oncology Center, Lausanne
 2006 – 2010 Director, Division of Experimental Oncology, CePO-UNIL-CHUV, Lausanne

9. Awards and Honors

2022 – present Member of the Senate of the Swiss Academy of Medical Sciences (SAMW)
 2008 Leenaards Prize (with Drs. J. Prior, O. Michielin and Y. Seimbille)
 1995 – 2000 SCORE Career Development Award, SNF
 1992 Fellowship from the American Heart Association
 1992 and 1993 Fellowship from the *Fondazione Ticinese per la Ricerca sul Cancro*
 1985 Fellowship for the PG in Exp Medicine and Biology, University of Zürich
 1991 Fellowship from the *Jubiläumsstiftung der Rentenanstalt*
 1989 and 1990 Fellowship from the Swiss National Science Foundation

10. Scientific committees and scientific advisory boards, past and present (Institutes and Agencies)

Over 20, including: Swiss Cancer League, Yamagiwa-Yoshida Memorial international cancer study grants of the UICC, Geneva, Switzerland; American Cancer Society, Cancer Research UK, Belgian

Science Policy Office, DFG, INSERM; HERES; AERES, Southern Europe New Drugs Organization, *Institut National du Cancer*, Paris; Tumor registry Fribourg), Bellinzona Institutes of Sciences (BIOS+), Bellinzona.

11. Consulting activities and scientific advisory boards, past and present (Companies)

Present: Abologix, Geneva. Past: Debiopharm, Lausanne; Compex Médical, Ecublens; ProStrakan, Paris; Thrombogenics, Dublin/New York; GIRUS Life sciences, San José, CA

12. Reviewer activities

- Granting agencies** Over 25 international agencies, including: American Cancer Society, Association for International Cancer Research, Cancer Research UK, Dutch Cancer Society, Deutsche Forschungsgemeinschaft, International Association for Cancer Research, Science Foundation Ireland, Swiss National Science Foundation, Swiss Cancer League
- Scientific journals** Over 60 scientific journals, including: Blood, Cancer Cell, Cancer Res., Circulation Res., EMBO; Lancet, Nat. Com; Nat. Med., Nat. Rev. Cancer, Nat. Clin. Pract. Oncol., Oncogene, J. Biol. Chem., J. Cell Biol., J. Clin. Invest.

13. Editorial boards

- 2005 Guest editor of The Journal of Leukocyte Biology
2008 – 2013 Section editor of Thrombosis and Hemostasis

14. Obtained external funding

- Past Over 45 grants worth over 25 Mio CHF of competitive funding obtained: SNF (9xRegular; 1xNRP37, Sinergia (2015-2018), 3 phases NCCR Molecular Oncology, 3 phases NCCR Bioinspired materials, 3 R'Equip, 3 ProDoc modules), Swiss Cancer League (6xRegular, 1xCCRP), Medic 2015-2018; 3R 2016-2018, Leenards Foundation, 3 Novartis Research Foundation, Roche Research Foundation, 2 CTI/KTI-Innosuisse, Geber RUF Stiftung, 3xEU FP7 (TUMIC, Integrated Project; SmArt, Marie Curie ITN; SmArteR, Marie Curie ITN), Medic Foundation; ISREC Foundation.
- Ongoing SNSF (2022-25), Swiss Cancer League (2022-25); NCCR bio-inspired materials (2022-25); Novartis Research Fund (2022-23); ISREC foundation (2022-24).

15. Patents

- 2022 Origami-fingerprinting based diagnostics (EP22200681.9)
2021-2022 Biomarker for breast cancer detection (EP 21151781.8; PCT/EP2022/050915)
2010, 2014, 2019 Biomarker for colorectal neoplasia (8697350; 0100330079; 19171645.5–1111)
2004, 2009, 2011 Combination therapy using anti-angiogenic substances (EU00357, 20040136949, 20090035270)

16. Business

- 2014 Co-founder of **Novigenix SA** (2014) a Start-Up dedicated to innovative cancer detection
2007 Co-founder of **Diagnoplex SA**, a Start-Up dedicated to early detection of colorectal cancer

17. Trainees

- Present 7 (2 postdoctoral fellows, 1 PhD and 1 MD thesis students, 3 Master thesis students)
Past >61 (MSci, MMed, MD thesis, PhD thesis, MD-PhD thesis, Postdoc)

18. Theses

MMed, M.Sci, MD and PhD : 49 directions and 60 committees (University of Fribourg, Lausanne, Geneva, Basel, Zürich, Nice, Bordeaux, Strasbourg, Paris VII, Rotterdam, EPFL).

19. Organized conferences and seminars

- 2014 SCOPES conference on Mathematical modeling of blood flow, Fribourg, September 4-5
2013 28th European Cytoskeletal Forum (with C. Chaponnier, S. Citi, M-L Pierrat, B. Wehrle-Haller, C Ampe), Fribourg, September 1-5
2012 Stem cells in vascular remodeling, SMART FP7 conference, Fribourg
2011 USGEB, Physiology symposium on imaging (with JP Montani, Z. Yang) Zürich
2011 SAMO Workshop on angiogenesis (with C. Sessa), Lucerne
2008 Cancer Research Campus Switzerland, January 26 – 27, 2008, USZ, Zürich,
2005 Clinical antiangiogenesis session at Gordon Research Conference on Angiogenesis and Microcirculation, August 14 – 19, Newport, RI, USA
2004 – 2007 Annual ESH interdisciplinary Euroconference on angiogenesis
Chairs: K. Alitalo, A. Bikfalvi, C. Betsholtz, C. Rüegg, A. Eichmann, G. Tobelem
2002 – 2017 International conference on tumor-host interaction and Angiogenesis *Fondazione Stefano Francini*, Monte Verità, Ascona, Switzerland (2002-2005-2007-2010-2013-2015-2017)
2002 Annual meeting of the Swiss Connective Tissue Society, Epalinges
1997 to 2002 Annual meetings of the Swiss Society for Oncology, CHUV, Lausanne

20. Invited seminars and lectures

- 1993 - present Over 250 invited seminars and lectures given at Institutes and Conferences in Switzerland, USA, France, UK, Italy, Belgium, Spain, Portugal, Austria, The Netherlands, Hungary, South Korea, Finland, Germany.